Results 181 to 190 of about 15,048 (225)

Pharmacokinetics and Pharmacodynamics of the Nitroimidazole Antimicrobials

Clinical Pharmacokinetics, 1999
Metronidazole, the prototype nitroimidazole antimicrobial, was originally introduced to treat Trichomonas vaginalis, but is now used for the treatment of anaerobic and protozoal infections. The nitroimidazoles are bactericidal through toxic metabolites which cause DNA strand breakage.
K C, Lamp, C D, Freeman, N E, Klutman, M K, Lacy   +3 more
openaire   +2 more sources

Tinidazole: A nitroimidazole antiprotozoal agent

Clinical Therapeutics, 2005
Tinidazole, a structural analogue of metrondazole, is an antiprotozoal agent that has been widely used in Europe and developing countries for >2 decades with established efficacy and acceptable tolerability. It was recently approved by the US Food and Drug Administration for the treatment of trichomoniasis, giardiasis, amebiasis, and amebic liver ...
Horatio B, Fung, Thien-Ly, Doan
openaire   +2 more sources

Clinical experience with nitroimidazoles as radiosensitizers

International Journal of Radiation Oncology*Biology*Physics, 1982
Abstract Clinical experience at Mount Vernon now includes 248 patients who have been given misonidazole (Ro 07–0582) and 57 patients who have been given desmethylmisonidazole (Ro 05–9963). Work with Ro 03–8799 is now beginning. The promise of chemical agents to improve the results of the radiotherapy is dependent upon effective levels of ...
S, Dische, M I, Saunders, P, Anderson, M R, Stratford, A, Minchinton   +4 more
openaire   +2 more sources

The synthesis of azomycin (2-Nitroimidazole)

Experientia, 1965
La sintesi del 2-nitroimidazolo e del 1-metil-2-nitroimidazolo per diazotasione e reasione di Gattermann a partire dai corrispondenti 2-aminoimidasoli dimostra che, in determinate condizioni, questi ultimi si comportano come composti a carattere aromatico.
G C, LANCINI, E, LAZZARI
openaire   +2 more sources

Radiosensitization of solid tumors by nitroimidazoles

International Journal of Radiation Oncology*Biology*Physics, 1978
Abstract Recently a new class of drugs has been identified by Adams et al. at the Gray Laboratory, which act as specific radiosensitizers of hypoxic cells. This sensitization results from their high electron affinity, and their presence at the time of irradiation abolishes the protection afforded by hypoxia.
J, Denekamp, J F, Fowler
openaire   +2 more sources

Studies on the action of nitroimidazole drugs. The products of nitroimidazole reduction.

Biochemical pharmacology, 1983
The electron requirements for the electrolytic reduction of misonidazole, metronidazole and 4(5)-nitroimidazole have been measured using high-resolution coulometry. Eleven of the labelled final reduction products of metronidazole (a 5-nitroimidazole) have been separated by high-performance liquid chromatography and identified. These appear to be formed
R J, Knox, R C, Knight, D I, Edwards
openaire   +1 more source

Nitroimidazoles as modifiers of nitrosourea pharmacokinetics

International Journal of Radiation Oncology*Biology*Physics, 1984
We have studied the effect of a number of nitroimidazole sensitizers of varying lipophilicity on the pharmacokinetics of CCNU in mice. It was found that the effectiveness of these compounds in producing pharmacokinetic effects correlated directly with their lipophilicity, viz.
F Y, Lee, P, Workman
openaire   +2 more sources

1-Trityl-4-nitroimidazole

Acta Crystallographica Section C Crystal Structure Communications, 1996
X-ray analysis confirmed the configuration of the title N1-alkylated C4-nitroimidazole inhibitor. The plane of the imidazole ring, sitting on an axis of the trityl propeller, bisects the angle between two phenyl rings, while the nitro group extends over the third.
E, Skrzypczak-Jankun, R G, Kurumbail
openaire   +2 more sources

Pharmacokinetics of Nitroimidazoles

1982
In this paper I want to try and show how a knowledge of the metabolism and pharmacokinetics of a compound helps us to understand the reasons why it may or may not satisfy the criteria desired of a particular drug. How we want a drug to behave depends on the use we have in mind for it. For example, in Fig.
T. R. Marten, R. J. Ruane, J. A. White, L. Clarke   +3 more
openaire   +1 more source

Nitroimidazoles as Anti-Tumor Agents

Anti-Cancer Agents in Medicinal Chemistry, 2011
At present cancer treatment is still a confusing problem. Great progress has been made in anti-tumor agents since a series of small molecules are approved by FDA as anti-tumor drugs. Nitroimidazoles is a kind of radiosensitizer with multiple bioactivities used in cancer treatment since 1950s.
Kai, Liu, Hai-Liang, Zhu
openaire   +2 more sources